The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Some of it is in the new Boston home of Eli Lilly & Co ., a $700 million research and development facility along Fort Point ...

Healthcare Opportunities Fund seems to offer a solid balance of capital stability and income. Read why THQ CEF is a Hold.

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. | Eli Lilly has spent the last several years reintroducing itself to the public via a ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

American Medical Association named John J. Whyte, MD, MPH as its next CEO and EVP, effective July 1. Centivo hired Sarah ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

U.S. equities were mixed at midday, with the Dow Jones Industrial Average and S&P 500 slightly higher and the Nasdaq ...